Connect Biopharma of Suzhou Raises $55 Million for Immune Disease Therapies

Connect Biopharma, a clinical-stage Suzhou company, completed a $55 million Series B financing to support clinical trials of immune modulators for autoimmune diseases. Connect is currently conducting two Phase II clinical studies of its lead candidate, CBP-307, in patients with ulcerative colitis and Crohn's disease. In Q1 2019, it expects to start a Phase Ib study of its second drug candidate CBP-201 in atopic dermatitis patients. The funding was led by new investor Advantech Capital. Two years ago, Connect raised $25 million in a Series A round. More details....

Share this with colleagues:

More From BioPortfolio on "Connect Biopharma of Suzhou Raises $55 Million for Immune Disease Therapies"